Global pharma major Lupin Limited announced the launch of Dasatinib Tablets in the United States, a generic equivalent of Bristol-Myers Squibb’s Sprycel®. The drug, used in treating certain types of leukemia, represents a significant addition to Lupin’s oncology portfolio, tapping into a billion-dollar U.S. market.
Show moreStay Ahead – Explore Now! Nifty IT Index Slips As Tech Stocks Face Pressure
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
